With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications
You may also be interested in...
Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up
MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years
Piramal Diagnostics In Sell-off Talks With SRL; 20 Percent Annual Growth Draws Big Investors To India
MUMBAI - After the company has vehemently denied rumors on the topic in the past, strong speculation has resurfaced that India's Piramal Diagnostics is close to selling off its diagnostics business to Malvinder Singh-controlled SRL - known earlier as Specialty Ranbaxy Laboratories
Ajay Piramal Aims At Lead Ranks In CRAMS, OTC And Critical Care Business; Reveals Details On Abbott Deal
MUMBAI - Giving up one flourishing unit seems to have created larger business opportunities for a few others that form part of Indian industrialist Ajay Piramal's enterprise Piramal Healthcare